| 1.32 0.01 (0.76%) | 01-09 13:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.57 | 1-year : | 1.83 |
| Resists | First : | 1.34 | Second : | 1.57 |
| Pivot price | 1.13 |
|||
| Supports | First : | 1.13 | Second : | 1 |
| MAs | MA(5) : | 1.17 |
MA(20) : | 1.14 |
| MA(100) : | 1.18 |
MA(250) : | 1.18 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 77.1 |
D(3) : | 56.1 |
| RSI | RSI(14): 69.6 |
|||
| 52-week | High : | 1.54 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANTX ] has closed It is unclear right now based on current values. 73.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.35 - 1.35 | 1.35 - 1.36 |
| Low: | 1.07 - 1.07 | 1.07 - 1.08 |
| Close: | 1.31 - 1.32 | 1.32 - 1.33 |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Wed, 07 Jan 2026
Eizen, AN2 Therapeutics COO, sells $25k in ANTX stock By Investing.com - Investing.com Nigeria
Wed, 07 Jan 2026
An2 therapeutics (ANTX): cfo Day sells $8883 in shares - Investing.com
Wed, 07 Jan 2026
An2 therapeutics CSO prior sells $6507 in stock - Investing.com
Tue, 11 Nov 2025
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) - BioSpace
Thu, 04 Sep 2025
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation - simplywall.st
Tue, 25 Mar 2025
AN2 Therapeutics Inc. (ANTX) reports earnings - qz.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 25.3 (%) |
| Held by Institutions | 39.3 (%) |
| Shares Short | 41 (K) |
| Shares Short P.Month | 48 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -46 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -1.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|